Brian Conn Email & Phone Number

Mountain View, Ca, Us

San Diego, Us

San Francisco Bay Area, Us

Thebarton, South Australia, Au

Biosensis specializes in antibodies and reagents for Neuroscience, with particular emphasis on neurotrophins and neurotrophin receptors.

Pleasanton, California, Us

Carlsbad, Ca, Us

Ra Med (NYSEA: RMED)has developed a minimally-invasive excimer laser and catheter system to treat vascular blockages. I joined in Q2 of 2022 to help identify and pursue strategic options. After a thorough evaluation of alternatives, the company decided to move forward on a reverse merger with Catheter Precision, a medical device company focused on the field of cardiac electrophysiology. On September 12, 2022, we announced signing a merger agreement which was closed on January 9, 2023. I am currently helping to complete the integration and ensuring that the newly-combined company stays compliant with reporting requirements during the transition.

San Diego, California, Us

San Diego, Ca, Us

Quantapore Inc. is developing a novel, nanopore based nucleic acid sequencing technology. Unlike other nanopore approaches, Quantapore utilizes an optical read out which results in lower cost and higher throughput compared to electrical data acquisition.

San Diego, California, Us

Imagion Biosystems has developed a novel imaging technology that can detect, locate and characterize solid tumors at a much greater level of sensitivity that other diagnostic methods. I joined Imagion in 2016 when it was a subsidiary of Manhattan Scientifics Inc. (MSI) and in need of funding to further develop the technology and prepare for human studies. In late 2016 the Company was spun out from MSI and we raised $4.6 million in two separate seed round. In June 2017, Imagion was listed on the Australia Stock Exchange and we raised AUD $12 million in a fully subscribed offering.

Helping early and growth-stage companies: - Raising capital - M&A execution and integration - Overseas operations - Business startups - Financial and operational management

Fremont, Ca, Us

DiscoverX is a drug discovery services company that provides pharma with safety and efficacy information about their compound libraries without conducting expensive animal and human studies. DiscoverX services enable companies to focus their resources on drug candidates that have the highest probability of success.I joined DiscoverX in 2016 to prepare the company for sale and assist the CEO with the process. In July 2017, Eurofins Scientific announced the acquisition of DiscoverX.

Verdezyne is a privately-held industrial biotechnology company that uses engineered micro-organisms to produce industrial chemicals from agricultural by-products. When I joined as CFO, it was a small, underfunded, research-stage company with no functioning Finance, HR or Marketing capabilities. Since then I raised $160 million in equity, debt and grants, created a business development and administrative infrastructure positioning Verdezyne to begin construction of its first commercial plant in Malaysia in 2016.

Canyonside Advisors provides services to businesses looking to monetize intellectual property, raise capital and complete an M&A transaction.

Atlanta, Ga, Us

Us

MicroIslet was a publicly held, early-stage life science company working on a novel therapy for type 1 diabetes. I joined as CFO when the Company had exhausted its existing funding sources and had been unsuccessful at attracting new investors. I structured a recapitalization to reduce its debt load, cut costs and began rigorous financial planning. Unfortunately, the convergence of the 2008 capital market collapse, along with MicroIslet’s situation made it impossible to continue operations. In 2009, the company converted its reorganization to Chapter 7 liquidation and we sold off the assets.

Burlington, Ma, Us

Following the acquisition by Millipore, I accepted a position with the company’s $650 million Bioscience Division. My responsibilities related primarily to integration activities, which included harmonization of reporting systems, transferring accounting functions to headquarters and overall financial management of the legacy businesses. During this time I also served as the financial due diligence lead on three acquisition projects.

After acquiring Chemicon, Serologicals kept the original management team intact to run a newly created Research Division. Through a combination of 15% to 20% organic growth and acquisitions totaling approximately $300 million, the Division grew from $50 million in 2003 to $140 million in 2005. During this period, I led diligence on four completed acquisitions, served as a steering committee member and functional lead on an SAP implementation and participated in numerous business initiatives. As Serologicals was a public company, we implemented Sarbanes-Oxley controls with no deficiencies noted. In March 2006, I joined a small team of company executives to execute the sale of the Company. On July 14, Millipore Corporation acquired Serologicals for $1.4 billion.

Us

Chemicon was a privately held biological research tools company with revenues of $27 million in 2000, which grew to over $40 million in 2002. As CFO, I was in charge of Finance and IT, including M&A due diligence, treasury as well as roles in operational aspects of the business. In June 2002, I assumed management of Marketing and Product Management. In late 2002, I organized a limited auction of the company and sold Chemicon to Serologicals Corporation for $98 million in April 2003.

VISTA was a publicly held internet real estate information company, which grew from $7 million in 1995 to $85 million in 2000. Most of this growth occurred as a result of several strategic acquisitions. During this period the company achieved a significant turnaround in profitability.- Conducted diligence, valuation and integration of seven acquisitions in a two-year period.- Managed treasury functions and raised nearly $90 million in capital through private equity investors and commercial lending arrangements.- Led the development of several custom software applications including order entry, contract management and a Web-based sales information system. - Supervised and participated in the company’s legal affairs and communications with investors, investment analysts and business press. - Participated in a variety of strategic initiatives and ventures including restructurings, business startups, partnerships and technology projects.

Bachelor Of Science, Finance

Aa, Business

Education record